Anti-Leucine-Rich, Glioma-Inactivated Protein 1 (LGI1), Spinal Fluid
Also known as: Autoimmune Dementia Panel Spinal Fluid, Paraneoplastic
Use
Leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis is a rare autoimmune voltage-gated potassium channel complex (VGKC) antibody-associated limbic encephalitis. Specifically, it is classified as an ant neuronal surface antigen- or ant-synaptic protein-associated autoimmune encephalitis. In addition to the common symptoms of limbic encephalitis such as cognitive impairment, seizures and psychiatric disorders, this disease is also associated with faciobrachial dystonic seizure (FBDS) and refractory hyponatremia. Unlike other limbic encephalitides, LGI1 antibody encephalitis is rarely accompanied by tumors and shows a good response to immunotherapy.
Special Instructions
Not provided.
Limitations
This test was developed and its performance characteristics determined by Labcorp in accordance with CLIA requirements. This test has not been cleared or approved by the Food and Drug Administration.
Methodology
Immunoassay (Immunofluorescence)
Biomarkers
LGI1 Antibody
Protein
LOINC Codes
- 90830-1 - LGI1 Ab CSF Ql CBA IFA
- 90830-1 - LGI1 Ab CSF Ql CBA IFA
- 90831-9 - LGI1 Ab Titr CSF CBA IFA
Result Turnaround Time
4 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
1 mL
Container
Sterile plastic tube
Storage Instructions
Room temperature
Causes for Rejection
Gross hemolysis; grossly lipemic; gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
Other tests from different labs that may be relevant